READ THE FULL COSM RESEARCH REPORT
Cosmos Health (NASDAQ: COSM) continues to demonstrate encouraging progress in its transformation into a more diversified, higher-growth global healthcare company. Its latest verified business announcement provides additional evidence of the rapid expansion of its U.S. direct-to-consumer subscription business, an initiative that could materially improve the company’s revenue mix, profitability, and long-term financial performance. At the same time, Cosmos has implemented a 1-for-20 reverse stock split, a corporate action that could help support its Nasdaq listing and provide a more stable foundation for pursuing its growth strategy.
Although reverse stock splits often create uncertainty for investors, the important distinction for Cosmos that we want to make is that the corporate restructuring is occurring alongside measurable improvements in its underlying business. The company’s expanding U.S. subscription operations, established pharmaceutical distribution network, growing contract manufacturing business, and international proprietary brands provide multiple avenues for future revenue growth.
Cosmos Health is a vertically integrated healthcare company with operations spanning pharmaceutical distribution, contract manufacturing, branded nutritional supplements, and digital healthcare. Its CosmoFarm distribution business serves more than 1,500 pharmacies, while Cana Laboratories provides pharmaceutical manufacturing capabilities. The company also markets proprietary healthcare products internationally and has increasingly emphasized direct-to-consumer e-commerce as a means of establishing higher-margin, recurring revenue streams.
U.S. Subscription Growth Provides an Important New Revenue Engine
The latest announcement highlights the remarkable early growth of Cosmos’ U.S. subscription platform, which launched in July and began scaling aggressively in mid-September.
As of October 31, Cosmos reported 12,532 active U.S. subscriptions, representing a net increase of 11,544 during October alone. These subscriptions represented approximately 29,500 product units and generated $1.83 million in monthly subscription value, equivalent to approximately $22 million on an annualized basis.
This is a very encouraging development to us because it demonstrates how quickly Cosmos has been able to establish a recurring customer base in the United States. Rather than depending entirely on individual purchases, the subscription model creates ongoing relationships in which customers receive products regularly, potentially improving revenue visibility, customer lifetime value, and the efficiency of future marketing expenditures.
Actual U.S. e-commerce sales during October totaled approximately $1.67 million, including $1.02 million attributable to subscriptions, meaning recurring purchases accounted for roughly 61% of monthly online sales. The company also reported approximately 19,100 orders from 234,500 online store sessions, demonstrating meaningful consumer engagement with its digital platform.
Importantly, the $22 million annualized subscription value represents the current subscription base valued at standard renewal pricing rather than revenue already earned or guaranteed future sales. Actual recurring revenue will depend on customer retention, successful renewals, and other operating factors. Nevertheless, the rapid accumulation of subscriptions provides encouraging evidence that Cosmos’ direct-to-consumer strategy is gaining traction.
We believe this changing revenue mix could become an important driver of operating leverage. As Cosmos develops a larger subscription base, the costs associated with digital infrastructure, fulfillment, marketing, and administration may be distributed across a growing volume of customer orders. If customer retention remains strong and acquisition costs are controlled, incremental subscription revenue could contribute disproportionately to operating profitability.
Reverse Stock Split Could Help Support the Company’s Next Phase
Effective November 13, Cosmos implemented a 1-for-20 reverse stock split, consolidating every 20 existing common shares into one post-split share.
From our perspective, the action will help Cosmos address Nasdaq’s minimum bid price requirements, support continued exchange listing, and potentially make its shares more accessible to investors whose investment guidelines discourage ownership of very low-priced securities.
Maintaining its Nasdaq listing is especially important for a company pursuing expansion, as exchange visibility can support liquidity, institutional awareness, and access to capital markets.
Broader Growth Strategy Reinforces the Investment Opportunity
The positive developments in U.S. e-commerce are part of a broader effort by management to build a diversified healthcare business with multiple complementary revenue sources
Cosmos previously announced preliminary revenue of approximately $54.3 million for the first nine months of 2026, representing 19% growth over the prior-year period. Management has reaffirmed its expectation that full-year revenue will surpass $90 million, implying approximately 38% annual growth and a particularly strong fourth quarter.
Meanwhile, Cana Laboratories has built a contract manufacturing pipeline exceeding 32.7 million units, while CosmoFarm continues expanding pharmaceutical distribution volumes. The company’s branded products are marketed in more than 40 countries, providing international diversification alongside its rapidly growing U.S. operations.
Management has also established longer-term financial targets, including $200.6 million in annual revenue and $44.2 million in adjusted EBITDA by 2029. These ambitious projections depend on successful execution and should not be interpreted as assured outcomes. Nevertheless, they illustrate management’s intention to transition Cosmos toward a significantly larger and more profitable operating structure.
Perhaps the most attractive element of this strategy in our view is the combination of established distribution and manufacturing capabilities with a rapidly expanding direct-to-consumer business. The existing operations provide product development, production, sourcing, and distribution infrastructure, while the e-commerce platform creates opportunities for higher-margin sales and recurring customer relationships.
Investment Outlook
Cosmos Health enters the final months of 2026 with encouraging operating momentum and several potential catalysts for continued growth. The rapid development of its U.S. subscription business is particularly meaningful because it provides evidence that management’s strategy of increasing exposure to higher-margin, recurring revenue opportunities is beginning to produce tangible results.
The reverse stock split should be viewed primarily as a capital markets and listing-related measure rather than a reflection of deteriorating operating fundamentals. While the transaction introduces certain shareholder considerations, including the potential for volatility and future dilution, it also occurs at a time when the company is reporting expanding sales, strong subscription growth, and ambitious plans for further development.
The company’s ability to convert its expanding subscription base into sustained revenue, positive cash flow, and improving earnings margins will ultimately determine the success of this transformation. Customer retention, marketing efficiency, and the achievement of management’s fourth-quarter financial targets will be particularly important indicators.
For investors, we believe the compelling aspect of Cosmos Health is the growing potential disconnect between the challenges reflected in its recent share-price history and the improvements taking place in its underlying business. A rapidly expanding U.S. subscription platform, established pharmaceutical operations, global distribution capabilities, and a strategy emphasizing higher-margin revenue provide opportunities for substantial operating improvement.
If Cosmos continues delivering on its growth objectives as we expect while maintaining financial discipline and limiting shareholder dilution, the company’s improving business fundamentals could eventually support a meaningful reassessment of its investment value.
SUBSCRIBE TO ZACKS SMALL CAP RESEARCH to receive our articles and reports emailed directly to you. Please visit our website for additional information on Zacks SCR.
DISCLOSURE: Zacks SCR has received compensation from the issuer directly, from an investment manager, or from an investor relations consulting firm, engaged by the issuer, for providing research coverage for a period of no less than one year. Research articles, as seen here, are part of the service Zacks SCR provides and Zacks SCR receives payments totaling a maximum fee of up to $50,000 annually for these services provided to or regarding the issuer. Full Disclaimer HERE.
